Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1978 1
1980 3
1984 3
1986 2
1987 1
1988 2
1989 1
1990 4
1991 7
1992 7
1993 7
1994 16
1995 14
1996 13
1997 11
1998 13
1999 14
2000 12
2001 8
2002 14
2003 15
2004 12
2005 16
2006 25
2007 15
2008 16
2009 17
2010 20
2011 23
2012 19
2013 18
2014 13
2015 19
2016 23
2017 15
2018 15
2019 17
2020 15
2021 13
2022 11
2023 3
2024 5
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Results by year

Filters applied: . Clear all
Page 1
Dermatophagoides pteronyssinus cluster immunotherapy. A controlled trial of safety and clinical efficacy.
Tabar AI, Muro MD, García BE, Alvarez MJ, Acero S, Rico P, Olaguíbel JM. Tabar AI, et al. J Investig Allergol Clin Immunol. 1999 May-Jun;9(3):155-64. J Investig Allergol Clin Immunol. 1999. PMID: 10412677 Clinical Trial.
We designed a cluster schedule of immunotherapy for patients allergic to Dermatophagoides pteronyssinus to reach the maximal recommended dose in 7 weeks. We compared its safety and clinical efficacy with those of a conventional schedule in a controlled trial. ...In …
We designed a cluster schedule of immunotherapy for patients allergic to Dermatophagoides pteronyssinus to reach the maximal r …
A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study.
Suratannon N, Limsuwan T, Tantilipikorn P, Chatchatee P, Saengapaswiriya A, Boonpiyathad T, Thongngarm T, Roongpuvapaht B, Chantaphakul H, Kulalert P, Thanaviratananich S, Sangsupawanich P, Fooanant S, Manuyakorn W, Chusakul S, Piboonpochanun O, Apornpong T, Wongpiyabovorn J, Ruxrungtham K; MITAR Study Group. Suratannon N, et al. Asian Pac J Allergy Immunol. 2024 Sep;42(3):233-245. doi: 10.12932/AP-221123-1735. Asian Pac J Allergy Immunol. 2024. PMID: 39417769 Free article. Clinical Trial.
METHODS: We conducted a randomized, placebo-controlled trial comparing HDM SCIT against placebo in Dermatophagoides pteronyssinus (Der p) sensitized. All patients received standard of care according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline, inc …
METHODS: We conducted a randomized, placebo-controlled trial comparing HDM SCIT against placebo in Dermatophagoides pteronyssinus …
Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.
Woehlk C, Ramu S, Sverrild A, Nieto-Fontarigo JJ, Vázquez-Mera S, Cerps S, Pulga A, Andreasson LM, Eriksen LL, Dyhre-Petersen N, Menzel M, Klein DK, Hansen S, Uller L, Porsbjerg C. Woehlk C, et al. Am J Respir Crit Care Med. 2023 May 1;207(9):1161-1170. doi: 10.1164/rccm.202209-1708OC. Am J Respir Crit Care Med. 2023. PMID: 36701676 Free PMC article. Clinical Trial.
Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
Tabar AI, González Delgado P, Sánchez Hernández C, Basagaña Torrento M, Moreno Benítez F, Arina M. Tabar AI, et al. J Investig Allergol Clin Immunol. 2015;25(1):40-6. J Investig Allergol Clin Immunol. 2015. PMID: 25898693 Free article. Clinical Trial.
BACKGROUND: Immunologically enhanced subcutaneous specific immunotherapy (SCIT) has been developed with a fast and simplified updosing phase containing equal parts of the house dust mites (HDM) Dermatophagoides pteronyssinus and Dermatophagoides farinae …
BACKGROUND: Immunologically enhanced subcutaneous specific immunotherapy (SCIT) has been developed with a fast and simplified updosing phase …
Clinical Trial With a Depigmented, Polymerized Mite Mixture Extract at Maximum Concentrations.
Vidal C, Romero L, Lopez-Freire S, Carballada-Gonzalez F, Garcia-Robaina JC, Gonzalez-Fernandez T, Mendez-Brea P, Nieto E, Ruiz-Garcia M. Vidal C, et al. Immun Inflamm Dis. 2024 Dec;12(12):e70090. doi: 10.1002/iid3.70090. Immun Inflamm Dis. 2024. PMID: 39698951 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatophagoides pteronyssinus/Blomia tropicalis (Dpt/Bt) and Dermatophagoides pteronyssinus/Lepidoglyphus destructor (Dpt/Ld …
OBJECTIVE: To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatopha …
Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy.
Bordas-Le Floch V, Berjont N, Batard T, Varese N, O'Hehir RE, Canonica WG, van Zelm MC, Mascarell L. Bordas-Le Floch V, et al. Allergy. 2022 Apr;77(4):1263-1273. doi: 10.1111/all.15107. Epub 2021 Oct 6. Allergy. 2022. PMID: 34551124 Clinical Trial.
Herein, we aim to explore changes in allergen-specific IgG2 in individuals undergoing house dust mite immunotherapy (HDM-AIT) and explore whether the interrelationship with other humoral responses (i.e., IgG4 and IgE) may discriminate between high and low responders. METHODS: Lev …
Herein, we aim to explore changes in allergen-specific IgG2 in individuals undergoing house dust mite immunotherapy (HDM-AIT) and explore wh …
Maternal atopy and parity.
Sunyer J, Antó JM, Harris J, Torrent M, Vall O, Cullinan P, Newman-Taylor A; AMICS study. Asthma Multi-centre Infants Cohort Study. Sunyer J, et al. Clin Exp Allergy. 2001 Sep;31(9):1352-5. doi: 10.1046/j.1365-2222.2001.01187.x. Clin Exp Allergy. 2001. PMID: 11591184 Clinical Trial.
452 results